Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
Claims What is claimed is: 1. A method of decreasing blood glucose levels in an animal comprising administering to said animal an effective amount of a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B. 2. The method according to claim 1, wherein said compound is an antisense oligonucleotide. 3. The method according to claim 2, wherein said antisense oligonucleotide has a sequence comprising SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235, 236, 237, 239 or 240. 4. The method according to claim 2, wherein said antisense oligonucleotide is a sequence of up to 30 nucleobases in length comprising at least an 8 nucleobase portion of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235, 236, 237, 239 or 240. 5. The method according to claim 2, wherein said antisense oligonucleotide has a sequence consisting of SEQ ID NO: 166. 6. The method according to claim 2, wherein said antisense oligonucleotide has a sequence consisting of SEQ ID NO: 20. 7. The method according to claim 2, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 8. The method according to claim 7, wherein the modified internucleoside linkage is a phosphorothioate linkage. 9. The method according to claim 2, wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 10. The method according to claim 9, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 11. The method according to claim 2, wherein the antisense oligonucleotide comprises at least one modified nucleobase. 12. The method according to claim 11, wherein the modified nucleobase is a 5-methylcytosine. 13. The method according to claim 2, wherein the antisense oligonucleotide is a chimeric oligonucleotide. 14. The method according to claim 1, when said compound is administered as a composition comprising said compound and a pharmaceutically acceptable carrier or diluent. 15. The method according to claim 14, wherein said composition further comprises a colloidal dispersion system. 16. The method according to claim 1, wherein the animal is a diabetic animal. 17. The method according to claim 16, wherein the diabetic animal has Type 2 diabetes. 18. The method according to claim 1, wherein the animal is a human or a rodent. 19. The method according to claim 1, wherein the blood glucose levels are plasma glucose levels or serum glucose levels. 20. A method of preventing or delaying the onset of an increase in blood glucose or plasma insulin levels in an animal comprising administering to said animal an effective amount of a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B. 21. The method according to claim 20, wherein said antisense oligonucleotide has a sequence comprising SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235; 236, 237, 239 or 240. 22. The method according to claim 20, wherein said antisense oligonucleotide is a sequence of up to 30 nuceobases in length comprising at least an 8 nucleobase portion of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235, 236, 237, 239 or 240. 23. The method according to claim 20, wherein said compound is administered as a composition comprising said compound and a pharmaceutically acceptable carrier or diluent. 24. The method according to claim 23, wherein said composition further comprises a colloidal dispersion system. 25. The method according to claim 20, wherein the animal is a diabetic animal. 26. The method according to claim 25, wherein the diabetic animal has Type 2 diabetes. 27. The method according to claim 20, wherein the animal is a human or a rodent. 28. The method according to claim 20, wherein the blood glucose levels are plasma glucose levels or serum glucose levels. 29. The method according to claim 20, wherein said compound is an antisense oligonucleotide. 30. The method according to claim 29, wherein said antisense oligonucleotide has a sequence consisting of SEQ ID NO: 166. 31. The method according to claim 29, wherein said antisense oligonucleotide has a sequence consisting of SEQ ID NO: 20. 32. The method according to claim 29 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 33. The method according to claim 32, wherein the modified internucleoside linkage is a phosphorothioate linkage. 34. The method according to claim 29, wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 35. The method according to claim 34, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 36. The method according to claim 29, wherein the antisense oligonucleotide comprises at least one modified nucleobase. 37. The method according to claim 36, wherein the modified nucleobase is a 5-methylcytosine. 38. The method according to claim 29, wherein the antisense oligonucleotide is a chimeric oligonucleotide. 39. A method of decreasing plasma insulin levels in an animal comprising administering to said animal an effective amount of a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B. 40. The method according to claim 39, wherein said compound is an antisense oligonucleotide. 41. The method according to claim 40, wherein said antisense oligonucleotide has a sequence comprising SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235, 236, 237, 239 or 240. 42. The method according to claim 40, wherein said antisense oligonucleotide is a sequence of up to 30 nucleobases in length comprising at least an 8 nucleobase portion of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235, 236, 237, 239 or 240. 43. The method according to claim 40, wherein said antisense oligonucleotide has a sequence consisting of SEQ ID NO: 166. 44. The method according to claim 40, wherein said antisense oligonucleotide has a sequence consisting of SEQ ID NO: 20. 45. The method according to claim 40, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 46. The method according to claim 45, wherein the modified internucleoside linkage is a phosphorotioate linkage. 47. The method according to claim 40, wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 48. The method according to claim 47, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 49. The method according to claim 40, wherein the antisense oligonucleotide comprises at least one modified nucleobase. 50. The method according to claim 49, wherein the modified nucleobase is a 5-methylcytosine. 51. The method according to claim 40, wherein the antisense oligonucleotide is a chimeric oligonucleotide. 52. The method according to claim 39, wherein said compound is administered as a composition comprising said compound and a pharmaceutically acceptable carrier or diluent. 53. The method according to claim 52, wherein said composition further comprises a colloidal dispersion system. 54. The method according to claim 39, wherein the animal is a diabetic animal. 55. The method according to claim 54, wherein the diabetic animal has Type 2 diabetes. 56. The method according to claim 39, wherein the animal is a human or a rodent. 57. A method of treating or delaying the onset of Type 2 diabetes in an animal comprising administering to said animal an effective amount of a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B. 58. The method according to claim 57, wherein said compound is administered as a composition comprising said compound and a pharmaceutically acceptable carrier or diluent. 59. The method according to claim 58, wherein said composition further comprises a colloidal dispersion system. 60. The method according to claim 57, wherein the animal is a human or a rodent. 61. The method according to claim 57, wherein said compound is an antisense oligonucleotide. 62. The method according to claim 61, wherein said antisense oligonucleotide has a sequence comprising SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235, 236, 237, 239 or 240. 63. The method according to claim 61, wherein said antisense oligonucleotide is a sequence of up to 30 nuceobases in length comprising at least an 8 nucleobase portion of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235, 236, 237, 239 or 240. 64. The method according to claim 61, wherein said antisense oligonucleotide has a sequence consisting of SEQ ID NO: 166. 65. The method according to claim 61, wherein said antisense oligonucleotide has a sequence consisting of SEQ ID NO: 20. 66. The method according to claim 61, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 67. The method according to claim 66, wherein the modified internucleoside linkage is a phosphorothioate linkage. 68. The method according to claim 66, wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 69. The method according to claim 68, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 70. The method according to claim 66, wherein the antisense oligonucleotide comprises at least one modified nucleobase. 71. The method according to claim 70, wherein the modified nucleobase is a 5-methylcytosine. 72. The method according to claim 66, wherein the antisense oligonucleotide is a chimeric oligonucleotide. 